Revelation Biosciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Revelation Biosciences Inc.
- Former names
- Petra Acquisition Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- REVB
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001810560
- EIN
- 84-3898466
Board of directors
-
Curt H. LaBelle · DirectorSince 2023
-
George F. Tidmarsh · DirectorSince 2023
-
James Rolke · Director · Chief Executive OfficerSince 2023
-
Jennifer Carver · DirectorSince 2023
-
Jess Roper · DirectorSince 2023
-
Lakhmir S. Chawla · DirectorSince 2023
Chief executives
James Rolke
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 23, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
89.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 17, 2026 | Jennifer Carver Director | Grant or award | +32,011 | — | — |
| Aug 17, 2026 | Lakhmir S. Chawla Director | Grant or award | +32,011 | — | — |
| Aug 17, 2026 | Jess Roper Director | Grant or award | +32,011 | — | — |
| Aug 17, 2026 | Zygmont Chester Stanley III Officer (Chief Financial Officer) | Grant or award | +208,073 | — | — |
| Aug 17, 2026 | James Rolke Director, Officer (Chief Executive Officer) | Grant or award | +208,076 | — | — |
| Aug 17, 2026 | Zygmont Chester Stanley III Officer (Chief Financial Officer) | Gift | −208,073 | — | — |
| Aug 17, 2026 | Zygmont Chester Stanley III Officer (Chief Financial Officer) | Gift | +208,073 | — | — |
| Apr 30, 2026 | James Rolke Director, Officer (Chief Executive Officer) | Shares withheld for tax | −10,115 | $1.13 | $11,430 |
| Apr 30, 2026 | Zygmont Chester Stanley III Officer (Chief Financial Officer) | Shares withheld for tax | −13,285 | $1.10 | $14,614 |
| Feb 4, 2026 | Zygmont Chester Stanley III Officer (Chief Financial Officer) | Shares withheld for tax | −13,100 | $1.65 | $21,615 |
| Feb 3, 2026 | Jess Roper Director | Shares withheld for tax | −1,591 | $1.85 | $2,943 |
| Feb 3, 2026 | Lakhmir S. Chawla Director | Shares withheld for tax | −2,261 | $1.85 | $4,183 |
| Feb 3, 2026 | Jennifer Carver Director | Shares withheld for tax | −1,661 | $1.87 | $3,106 |
| Feb 3, 2026 | James Rolke Director, Officer (Chief Executive Officer) | Shares withheld for tax | −8,521 | $1.86 | $15,849 |
| Jan 8, 2026 | James Rolke Director, Officer (Chief Executive Officer) | Grant or award | +532,829 | $0.90 | $479,546 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.